- Home
- ACP vs IMTX Comparison
ACP vs IMTX Comparison
Compare ACP & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACP
- IMTX
- Stock Information
- Founded
- ACP 2010
- IMTX N/A
- Country
- ACP United States
- IMTX Germany
- Employees
- ACP N/A
- IMTX N/A
- Industry
- ACP Investment Managers
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACP Finance
- IMTX Health Care
- Exchange
- ACP Nasdaq
- IMTX Nasdaq
- Market Cap
- ACP 740.3M
- IMTX 865.5M
- IPO Year
- ACP N/A
- IMTX N/A
- Fundamental
- Price
- ACP $5.79
- IMTX $10.40
- Analyst Decision
- ACP
- IMTX Strong Buy
- Analyst Count
- ACP 0
- IMTX 5
- Target Price
- ACP N/A
- IMTX $15.00
- AVG Volume (30 Days)
- ACP 337.9K
- IMTX 914.4K
- Earning Date
- ACP 01-01-0001
- IMTX 11-17-2025
- Dividend Yield
- ACP 17.79%
- IMTX N/A
- EPS Growth
- ACP N/A
- IMTX N/A
- EPS
- ACP N/A
- IMTX N/A
- Revenue
- ACP N/A
- IMTX $152,823,253.00
- Revenue This Year
- ACP N/A
- IMTX N/A
- Revenue Next Year
- ACP N/A
- IMTX N/A
- P/E Ratio
- ACP N/A
- IMTX N/A
- Revenue Growth
- ACP N/A
- IMTX 83.61
- 52 Week Low
- ACP $5.55
- IMTX $3.30
- 52 Week High
- ACP $7.17
- IMTX $11.20
- Technical
- Relative Strength Index (RSI)
- ACP 43.00
- IMTX 83.00
- Support Level
- ACP $5.72
- IMTX $9.10
- Resistance Level
- ACP $5.93
- IMTX $9.54
- Average True Range (ATR)
- ACP 0.04
- IMTX 0.52
- MACD
- ACP -0.00
- IMTX 0.27
- Stochastic Oscillator
- ACP 38.11
- IMTX 95.95
About ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.